Drug Treatment-lipid disorders
Drug ↓ LDL ↓ TG Side Effects/Comments
statins 30–60% 10–25%
Ezetimibe ~24% —
Well tolerated
Bempedoic acid ~16% —
Hyperuricemia/gout; ↓ eGFR. CVOT under way.
PCSK9i 50–60% 15–25%
mAb inj SC q2-4w or siRNA inj SC q6mo
Fibrates 5–15% 35–50%
Myopathy risk ↑ w/ statin. ↑ Cr; ✓ renal fxn q6mo.
Ω-3 FA 5% ↑ 25–50%
EPA & DHA at doses of up to 4 g/d No benefit to low-dose supplementation
Resins ↓ LDL-C by ~20%, but not well tolerated; niacin ↑ HDL-C and ↓ TG & LDL-C; no effect on CV outcomes.